vs

Side-by-side financial comparison of CLOVER HEALTH INVESTMENTS, CORP. (CLOV) and NORTHERN OIL & GAS, INC. (NOG). Click either name above to swap in a different company.

NORTHERN OIL & GAS, INC. is the larger business by last-quarter revenue ($610.2M vs $487.7M, roughly 1.3× CLOVER HEALTH INVESTMENTS, CORP.). CLOVER HEALTH INVESTMENTS, CORP. runs the higher net margin — -10.1% vs -11.6%, a 1.5% gap on every dollar of revenue. On growth, CLOVER HEALTH INVESTMENTS, CORP. posted the faster year-over-year revenue change (44.7% vs -72.6%). NORTHERN OIL & GAS, INC. produced more free cash flow last quarter ($43.2M vs $-69.0M). Over the past eight quarters, CLOVER HEALTH INVESTMENTS, CORP.'s revenue compounded faster (18.6% CAGR vs 4.3%).

Clover Health Investments, Corp. is an American health care company founded in 2014. The company provides Medicare Advantage (MA) insurance plans and operates as a direct contracting entity with the U.S. government. The company manages care for Medicare beneficiaries in 11 states and started trading publicly on January 8, 2021.

Marathon Oil Corporation was an American company engaged in hydrocarbon exploration. In November 2024, it was acquired by ConocoPhillips and absorbed into the company.

CLOV vs NOG — Head-to-Head

Bigger by revenue
NOG
NOG
1.3× larger
NOG
$610.2M
$487.7M
CLOV
Growing faster (revenue YoY)
CLOV
CLOV
+117.3% gap
CLOV
44.7%
-72.6%
NOG
Higher net margin
CLOV
CLOV
1.5% more per $
CLOV
-10.1%
-11.6%
NOG
More free cash flow
NOG
NOG
$112.2M more FCF
NOG
$43.2M
$-69.0M
CLOV
Faster 2-yr revenue CAGR
CLOV
CLOV
Annualised
CLOV
18.6%
4.3%
NOG

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
CLOV
CLOV
NOG
NOG
Revenue
$487.7M
$610.2M
Net Profit
$-49.3M
$-70.7M
Gross Margin
Operating Margin
-10.1%
Net Margin
-10.1%
-11.6%
Revenue YoY
44.7%
-72.6%
Net Profit YoY
-123.2%
-198.7%
EPS (diluted)
$-0.73

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CLOV
CLOV
NOG
NOG
Q1 26
$610.2M
Q4 25
$487.7M
$610.2M
Q3 25
$496.6M
$556.6M
Q2 25
$477.6M
$706.8M
Q1 25
$462.3M
$602.1M
Q4 24
$337.0M
$515.0M
Q3 24
$331.0M
$753.6M
Q2 24
$356.3M
$560.8M
Net Profit
CLOV
CLOV
NOG
NOG
Q1 26
$-70.7M
Q4 25
$-49.3M
$-70.7M
Q3 25
$-24.4M
$-129.1M
Q2 25
$-10.6M
$99.6M
Q1 25
$-1.3M
$139.0M
Q4 24
$-22.1M
$71.7M
Q3 24
$-9.2M
$298.4M
Q2 24
$7.4M
$138.6M
Gross Margin
CLOV
CLOV
NOG
NOG
Q1 26
Q4 25
80.4%
Q3 25
78.7%
Q2 25
82.8%
Q1 25
81.1%
Q4 24
77.4%
Q3 24
24.5%
85.8%
Q2 24
30.3%
82.0%
Operating Margin
CLOV
CLOV
NOG
NOG
Q1 26
Q4 25
-10.1%
-5.5%
Q3 25
-4.9%
-22.6%
Q2 25
-2.2%
24.9%
Q1 25
-0.3%
38.1%
Q4 24
-6.4%
25.8%
Q3 24
-2.7%
57.6%
Q2 24
2.0%
39.0%
Net Margin
CLOV
CLOV
NOG
NOG
Q1 26
-11.6%
Q4 25
-10.1%
-11.6%
Q3 25
-4.9%
-23.2%
Q2 25
-2.2%
14.1%
Q1 25
-0.3%
23.1%
Q4 24
-6.6%
13.9%
Q3 24
-2.8%
39.6%
Q2 24
2.1%
24.7%
EPS (diluted)
CLOV
CLOV
NOG
NOG
Q1 26
$-0.73
Q4 25
$-0.67
Q3 25
$-1.33
Q2 25
$1.00
Q1 25
$1.39
Q4 24
$0.71
Q3 24
$2.96
Q2 24
$1.36

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CLOV
CLOV
NOG
NOG
Cash + ST InvestmentsLiquidity on hand
$78.3M
$14.3M
Total DebtLower is stronger
Stockholders' EquityBook value
$308.7M
$2.1B
Total Assets
$541.0M
$5.4B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CLOV
CLOV
NOG
NOG
Q1 26
$14.3M
Q4 25
$78.3M
$14.3M
Q3 25
$31.6M
Q2 25
$25.9M
Q1 25
$33.6M
Q4 24
$194.5M
$8.9M
Q3 24
$288.0M
$34.4M
Q2 24
$254.8M
$7.8M
Total Debt
CLOV
CLOV
NOG
NOG
Q1 26
Q4 25
$2.4B
Q3 25
$2.3B
Q2 25
$2.4B
Q1 25
$2.3B
Q4 24
$2.4B
Q3 24
$2.0B
Q2 24
$1.9B
Stockholders' Equity
CLOV
CLOV
NOG
NOG
Q1 26
$2.1B
Q4 25
$308.7M
$2.1B
Q3 25
$340.9M
$2.2B
Q2 25
$344.2M
$2.4B
Q1 25
$336.1M
$2.4B
Q4 24
$341.1M
$2.3B
Q3 24
$342.2M
$2.3B
Q2 24
$324.9M
$2.1B
Total Assets
CLOV
CLOV
NOG
NOG
Q1 26
$5.4B
Q4 25
$541.0M
$5.4B
Q3 25
$559.7M
$5.5B
Q2 25
$575.0M
$5.7B
Q1 25
$583.7M
$5.7B
Q4 24
$580.7M
$5.6B
Q3 24
$653.0M
$5.1B
Q2 24
$674.2M
$4.7B
Debt / Equity
CLOV
CLOV
NOG
NOG
Q1 26
Q4 25
1.13×
Q3 25
1.05×
Q2 25
0.98×
Q1 25
0.96×
Q4 24
1.02×
Q3 24
0.84×
Q2 24
0.91×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CLOV
CLOV
NOG
NOG
Operating Cash FlowLast quarter
$-66.9M
$312.6M
Free Cash FlowOCF − Capex
$-69.0M
$43.2M
FCF MarginFCF / Revenue
-14.1%
7.1%
Capex IntensityCapex / Revenue
0.4%
31.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-69.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CLOV
CLOV
NOG
NOG
Q1 26
$312.6M
Q4 25
$-66.9M
$312.6M
Q3 25
$12.1M
$423.1M
Q2 25
$5.4M
$362.1M
Q1 25
$-16.3M
$407.4M
Q4 24
$34.8M
$290.3M
Q3 24
$50.0M
$385.8M
Q2 24
$44.8M
$340.5M
Free Cash Flow
CLOV
CLOV
NOG
NOG
Q1 26
$43.2M
Q4 25
$-69.0M
Q3 25
$11.4M
Q2 25
$4.8M
Q1 25
$-16.5M
Q4 24
$33.3M
Q3 24
$49.6M
Q2 24
$44.4M
FCF Margin
CLOV
CLOV
NOG
NOG
Q1 26
7.1%
Q4 25
-14.1%
Q3 25
2.3%
Q2 25
1.0%
Q1 25
-3.6%
Q4 24
9.9%
Q3 24
15.0%
Q2 24
12.5%
Capex Intensity
CLOV
CLOV
NOG
NOG
Q1 26
31.5%
Q4 25
0.4%
Q3 25
0.1%
Q2 25
0.1%
Q1 25
0.0%
Q4 24
0.5%
Q3 24
0.1%
Q2 24
0.1%
Cash Conversion
CLOV
CLOV
NOG
NOG
Q1 26
Q4 25
Q3 25
Q2 25
3.64×
Q1 25
2.93×
Q4 24
4.05×
Q3 24
1.29×
Q2 24
6.04×
2.46×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CLOV
CLOV

Segment breakdown not available.

NOG
NOG

Oil and Gas Sales$447.7M73%
Gain on Commodity Derivatives, Net$159.3M26%
Other Revenue$3.1M1%

Related Comparisons